Key HIV Studies Influencing My Practice Following AIDS 2022—Audio Redcap

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:

• Prevention strategies
• Data on doxycycline as postexposure prophylaxis for sexually transmitted infections in people with HIV (PWH) and those receiving pre-exposure prophylaxis (PrEP)
• Data on 6-month PrEP dispensing and HIV self-testing in Kenya
• Data on what women in Namibia want when it comes to PrEP
• Outcomes for transgender women in the HPTN 083 trial comparing long-acting (LA) cabotegravir (CAB) vs daily oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) as PrEP in transgender women and men who have sex with men
• Data on LA CAB for PrEP in women from an additional 1-year unblinded period of HPTN 084
• Oral therapies
• ALLIANCE study of bictegravir/FTC/tenofovir alafenamide vs dolutegravir + FTC/TDF for HIV/hepatitis B virus coinfection
• SIMPL’HIV Wk 144 outcomes comparing switch to dolutegravir + FTC vs continued 3-drug antiretroviral therapy (ART) in patients with virologic suppression
• LA therapies
• CARLOS study of patient and healthcare professional perspectives on switching from daily oral ART to LA CAB + rilpivirine
• CARISEL phase IIIb implementation study of CAB + rilpivirine for ART in Europe
• Lenacapavir resistance and injection-site reaction data from the CALIBRATE and CAPELLA studies
• Cure
• City of Hope case of patient with prolonged HIV-1 remission without ART after allogeneic stem cell transplant
• COVID-19 in PWH
• WHO data on in-hospital mortality from COVID-19 among PWH